Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of⦠read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
$13.64
Price-2.78%
-$0.39
$358.056m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$556k
-
1y CAGR-
3y CAGR-
5y CAGR-$37.917m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.26
-
1y CAGR-
3y CAGR-
5y CAGR$97.295m
$99.592m
Assets$2.297m
Liabilities$849k
Debt0.9%
-
Debt to EBITDA-$23.594m
-
1y CAGR-
3y CAGR-
5y CAGR